Quick Answer
Cadrenal Therapeutics, Inc. reported Diluted EPS of $6.64 per share (loss) for fiscal year 2025.
Cadrenal Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$6.64 | +23.9% |
| 2024 | -$8.73 | +6.0% |
| 2023 | -$9.29 | -992.9% |
| 2022 | -$0.85 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.31 | +39.9% | +29.9% |
| June 30, 2025 | -$1.87 | +16.5% | +10.5% |
| March 31, 2025 | -$2.09 | -34.0% | +4.1% |
| September 30, 2024 | -$2.18 | -115.8% | +2.7% |
| June 30, 2024 | -$2.24 | -2388.9% | -43.6% |
| March 31, 2024 | -$1.56 | -225.0% | -54.5% |
| September 30, 2023 | -$1.01 | -676.9% | -1022.2% |
| June 30, 2023 | -$0.09 | -228.6% | +81.3% |
- Cadrenal Therapeutics, Inc. showed an increase of +23.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, Cadrenal Therapeutics, Inc.’s diluted eps has declined by 681.2% (from $0.85 per share (loss) to $6.64 per share (loss)).
- The most recent figure is from Cadrenal Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: